Maze Therapeutics, Inc. (MAZE)

Maze Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022
Net Income	55.23	-100.42	-114.94
Depreciation & Amortization	3.57	4.09	3.82
Share-Based Compensation	-	8.75	6.74
Other Operating Activities	18.96	0.75	5.18
Operating Cash Flow	77.76	-86.83	-99.2
Capital Expenditures	-0.58	-0.44	-1.97
Change in Investments	-	-	-1.2
Investing Cash Flow	-0.58	-0.44	-3.17
Share Issuance / Repurchase	-	0.21	1.73
Debt Issued / Paid	-	16.18	-
Financing Cash Flow	38.77	16.39	1.73
Net Cash Flow	115.96	-70.88	-100.65
Free Cash Flow	77.19	-87.27	-101.17

Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).